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the inhibitory role of estrogen in the male HPG axis. 
Clinicians may consider this rare diagnosis for men in their 
late teens or early twenties, who have spontaneous initia-
tion of puberty, presenting with bone pain and continued 
linear growth.
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Introduction: Primary aldosteronism (PA) is associated 
with an increased risk of impaired glucose tolerance or type 
2 diabetes mellitus. Previous studies have reported that im-
paired insulin secretion and insulin sensitivity in PA may 
lead to impaired glucose tolerance. However, the relation-
ship between PA and glucose tolerance, and the factor asso-
ciated with these glucose metabolism abnormalities is not 
well understood. In particular, few studies have analyzed 
the association between aldosterone excess and insulin sen-
sitivity or resistance after the adjustment for other clin-
ical variables. In this study, we analyzed the associations 
between multiple clinical variables observed in PA and 
the indices of insulin sensitivity and resistance, using the 
result of 75 g oral glucose tolerance test (OGTT).Method: 
This was a retrospective observational study that analyzed 
the data of 646 patients with PA who underwent adrenal 
venous sampling and 75 g OGTT. The insulinogenic index 
and Matsuda index, indices of insulin secretion and sen-
sitivity, respectively, were calculated from the results of 
a 75 g OGTT. Correlations between these indices and the 
multiple clinical variables were analyzed. In addition, we 
performed multiple regression analyses to identify the in-
dependent explanatory variables of these indices.Results: 
Insulinogenic index had positive correlations with the body 
mass index (BMI), alanine aminotransferase (ALT) level, 
triglyceride (TGL) level, and potassium level, and negative 
correlations with both age and plasma aldosterone concen-
tration (PAC). In a multiple regression analysis, both the 
age (β = -0.231, p < 0.001) and potassium level (β = 0.175, 
p  =  0.002) were selected as the independent explanatory 
factors. The Matsuda index had positive correlations with 
the PAC and cortisol level after a 1 mg dexamethasone sup-
pression test (DST), and negative correlations with BMI, 
ALT level, TGL level, plasma renin activity (PRA), and 
potassium level. In a multiple regression analysis, BMI 
(β = -0.216, p < 0.001), ALT level (β = -0.290, p < 0.001), TGL 
level (β =  -0.225, p < 0.001), the cortisol level after 1 mg 
DST (β = 0.124, p = 0.009), and PRA (β = -0.119, p = 0.019) 
were selected as the independent explanatory factors.
Conclusion: In PA patients, older age and decreased potas-
sium levels were associated with impaired insulin secre-
tion. An increase in the variables associated with metabolic 
abnormalities such as BMI, ALT, and TGL were associated 
with decreased insulin sensitivity. In addition, we found 
that decreased PRA was associated with increased insulin 
sensitivity.
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Background: Patients with congenital adrenal hyper-
plasia (CAH) due to classic 21-hydroxylase deiciency have 
poor health outcomes related to inadequate glucocorticoid 
(GC) replacement. We compared disease control of adults 
with classic CAH treated with a modiied release hydro-
cortisone (MRHC), which replicates physiological diurnal 
cortisol secretion, versus standard GC therapy.
Methods: 6  month, open label, study in 122 patients 
randomised either to treatment with MRHC 
(Chronocort®, Diurnal Ltd, Cardiff, UK) twice daily 
at ~ 0700h & ~2300h, or to remain on their standard 
GC regimen (hydrocortisone, prednisolone, prednisone, 
dexamethasone). Patients had 24-hr proiling of serum 
17-hydroxyprogesterone (17-OHP) at baseline and for 
dose titration at 4 and 12 weeks. The primary eficacy 
endpoint was the change from baseline to 24 weeks in 
the natural logarithm of the mean of the 24-hr standard 
deviation score (SDS) proile for 17-OHP.
Results: Both groups achieved improved hormonal con-
trol at 24 weeks. The mean 24-hour 17-OHP SDS was sig-
niicantly lower on MRHC compared to standard GC at 4 
weeks (p = 0.0074) and 12 weeks (p = 0.019), but not at 24 
weeks. In post-hoc analyses at 24 weeks, MRHC treatment 
showed a greater reduction in 17-OHP SDS compared to 
standard GC in the morning, 0700-1500h (p = 0.0442) and 
a greater reduction in log transformed 17-OHP 24 hour 
AUC (p=0.0251). Deining a morning 17-OHP <1200ng/dl 
(<36  nmol/L) as good control, for patients not controlled 
at baseline 85% were well controlled at 24 weeks with 
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MHRC versus 50% on standard GC. For patients controlled 
at baseline 100% were controlled at 24 weeks on MHRC 
versus 84% with standard GC (p = 0.0018). The variability 
of 17-OHP over 24 hours was signiicantly reduced in the 
MRHC group compared to standard GC: the ratio of am-
plitude at 24 weeks divided by amplitude at baseline was 
for MRHC, 0.361 [95% CI: 0.235, 0.651], and standard GC, 
0.917 [0.773, 1.366]; (p  =  0.0001).There were no adrenal 
crises on MRHC and fewer stress doses despite similar in-
cidence of inter-current illness to the standard GC group 
which had 3 adrenal crises. MRHC was associated with 
patient reported beneit including restoration of menstru-
ation in 4 patients on MRHC and 1 on standard GC and 
two partner pregnancies in patients on MRHC and none on 
standard GC.
Discussion: This is the largest randomised controlled trial 
of GC treatment in CAH and showed that intensiication of 
therapy could improve control of the androgen-precursor, 
17-OHP, and that this hormonal control was superior in the 
morning with MRHC. MRHC reduced the luctuations in 
17-OHP such that in the majority of patients the 17-OHP 
proile was within the reference range throughout 24 hours, 
providing consistent and optimal disease control.
Conclusion: Diurnal cortisol replacement with a MRHC 
improves the biochemical control of classic CAH with a 
twice-daily therapeutic regimen.
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Introduction: Assessing the development and health 
status of children born after assisted reproductive 
techniques is very important. This also applies to so-
matic and neurological development. Little is known 
on the development of muscle tone in children. Aim of 
our study was to evaluate the somatic and neurological 
development in children born after intracytoplasmic 
sperm injection (ICSI) with special focus on proximal 
muscle tone.
Material and methods: A group of 82 singletons (ICSI) 
aged 5–9  years (42  M, 40 F) and a control group of 82 
singletons spontaneously conceived (SC), all with low mor-
bidity, were compared by age and sex. Comprehensive as-
sessment by endocrinologist, clinical anthropologist and 
pediatric neurologist was performed.
Results: Both ICSI and SC children had normal so-
matic development. In the standard neurological 
testing, motor development did not differ signiicantly 
in ICSI children compared with the general population. 
Nevertheless, some coordination abnormalities tested by 
diadochokinesis and by the inger-nose test, were found 
in all but 7 ICSI children (ICSI in 91 % versus SC in 9 %; 
p<0.001). A prominent hypotonia of upper girdle muscles 
tested by the scarf sign was found in all but 4 ICSI chil-
dren (ICSI in 95 % versus SC in 61 %; p<0.001). In the 
contrary, no difference was found for lower girdle muscle 
tone in ICSI versus SC children. Any of the factors tested 
for possible relationship to upper girdle muscle hypo-
tonia was not found to be signiicant.
Conclusions: As far as we know, this study is the irst 
evaluation of proximal muscle tone in ICSI children aged 
5 - 9 years. Subtle changes in the neurological status were 
revealed comparing ICSI and SC children, i.  e. the prom-
inent upper girdle muscle hypotonia and the coordination 
changes. The hypotonia can be explained by a slight change 
in the muscle tone maturation and movement coordina-
tion. The ICSI method very likely does not have any nega-
tive effect on the neurodevelopmental outcome of children. 
Nevertheless, the development of muscle tone and coordina-
tion in ICSI children should be monitored. Early diagnosis 
of these abnormalities helps to early initiation of appro-
priate therapy and thus avoids possible complications.
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Background: Hyperinsulinism is the most common cause 
of persistent hypoglycemia. It results from different ge-
netic defects, the most common being recessive and domi-
nant mutations in the ABCC8/KCNJ11 genes. The majority 
of recessive mutations have a poor response to Diazoxide, 
while dominant mutations are highly variable in both clin-
ical presentation and response to treatment. Prompt rec-
ognition and management is critical to avoid irreversible 
brain damage. Clinical case: A 38-week gestation male, 
born via emergent c-section due to decreased fetal move-
ment, presented with neonatal hypoglycemia. Pregnancy 
was uncomplicated and mother had a normal OGTT. 
Patient had a history of suspected sepsis, seizures, pul-
monary hypertension and respiratory distress requiring 
intubation. Blood glucose was undetectable at birth and 
required multiple dextrose 10% boluses. A critical sample 
with a glucose of 47 mg/dL showed an elevated insulin at 
30.3 m IU/mL with undetectable ketone levels. Lactic acid, 
ammonia, cortisol, GH, plasma amino acids, acylcarnitine 
proile and uric organic acids where all normal for a hypo-
glycemic state. He required intravenous glucose infusion 
with GIR up to 17 mg/kg/min to maintain normoglycemia. 
A  brain MRI at 11  days of life showed indings of white 
matter injury. Subsequent genetic testing identiied a het-
erozygous c.4051G>A (p.Val1351Met) variant in ABCC8, 
classiied as “of uncertain signiicance”. However, an entry 
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